Abstract 946P
Background
Hepatocellular carcinoma (HCC) patients (pts) with major vascular invasion (MVI) or extrahepatic metastases were generally recommended systemic treatment by guidelines, and pts have missed the opportunity for curative resection. Conversion therapy that can convert unresectable HCC into resectable HCC may improve patient survival. Here we report the Sintilimab plus Lenvatini as a conversion therapy for unresectable HCC.
Methods
Briefly, the main inclusion criteria of the study was: Aged 18 to 75 years unresectable HCC pts diagnosed pathologically and/or radiologically, with at least one measurable lesion (mRECIST). The criteria for Successful Conversion: 1. Child-Pugh score < 7. 2. ECOG PS score ≤1. 3. Downstaging to BCLC-A or PR according to mRECIST, and extrahepatic lesions can be resected at the same time. 4. Intact vascular structure of the reserved liver and sufficient FLR.
Results
A total of 137 pts were enrolled in the study by April 10, 2023 and accepted the Sintilimab plus Lenvatinib as conversion therapy,100 pts were finally included for evaluation, in which 58 pts with PVTT (39 pts were classified as VP4), 4 with IVCTT and 7 with both. 26 pts had extrahepatic metastases, and 92 pts were HBV-positive. According to mRECIST, the ORR was 54% and DCR was 77%. Successful conversion rate based on radiology was 51%, and 47% pts received hepatectomy. With a median follow-up of 17 months (range, 1-43), the median OS was 25 months (95% CI, 15.9–34.1) among all pts, the median OS of the pts was not reached [95% CI not reached] in the surgical group and 15 months (95% CI, 10.3–19.7) in the non-surgical group. The median RFS was 25 months (95% CI, 13.6–36.4) in the surgical group and the median PFS was 7 months (95% CI, 3.5–10.5) in the non-surgical group. All pts were evaluable for toxicity, and 83 (83%) pts had at least one treatment-related AE (TRAE). TRAEs occurring in ≥10% of pts were rash (27%), hypertension (18%), hand foot syndrome (17%), and diarrhoea (16%). 28 pts had grade 3 TRAEs.
Conclusions
The combination therapy of Sintilimab plus Lenvatinib can be reviewed as a reasonable and promising conversion therapy option for unresectable HCC with safety and effectiveness.
Clinical trial identification
ChiCTR1900023914.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18